drugset / Trial / NCT00546572
Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)
RandomizedParallel-groupDouble-blindPrevention
Summary
This study will evaluate the safety, tolerability and immunogenicity of study vaccines 13vPnC and 23vPS in older, healthy subjects who have previously received a dose of 23vPS at least 5 years ago. It will also evaluate the safety, tolerability and immunogenicity to a dose of 13vPnC 1 year after the initial dose of study vaccine.
Timeline
- Start
- 2007-11
- Primary completion
- 2010-07
- Completion
- 2010-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | 23vPS | Vaccine | 0.5 ml | Intramuscular |
| Subject | Prevnar 13 | Vaccine | 0.5 ml | Intramuscular |